- Subjects will be restaged at the end of Belinostat Cycle 3(-7 days), Belinostat Cycle 8(-14 days), end of Month 9(≤14 days) and end of Month 12 (≤14 days) post-Belinostat during AZT-based maintenance treatment. Subjects who have progression of disease at any of these time points will be taken off study treatment. At the end of Cycle 3 (of Belinostat), subjects who achieve a molecular complete response or maintain a clinical stable response may continue on the study.